 2. Subjects enrolling in Cohort A PomLD-dex must have received 2 prior treatment lines of anti-myeloma therapy. Subjects enrolling in Cohort B PomDaraLD-dex must have received 1 or 2 prior treatment lines of anti-myeloma therapy. 